Glycostem and Ghent University sign license agreement on NK cell therapy technology
- Significant positive effect on production time of Glycostem s lead product oNKord
, and future CAR-NK and TCR-NK therapies
OSS, Netherlands, Dec. 17, 2020 /PRNewswire/
Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic off-the-shelf Natural Killer (NK) cells, and Ghent University (UGent) have signed a license agreement for an innovative NK cell production technology. Ultimately, this agreement will bring significant benefit to targeted treatment of patients suffering from cancer. The agreement not only opens up new opportunities for development of NK-antibody combination therapies but also has significant positive impact on the production time of Glycostem s lead product oNKord
Glycostem announces treatment of first patient in pivotal phase I/IIa trial of oNKord in patients with Acute Myeloid Leukemia
OSS, Netherlands, Dec. 15, 2020 /PRNewswire/
Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic off-the-shelf Natural Killer (NK) cells, today announced that the first patient has been dosed in its pivotal phase I/IIa trial of oNKord for the treatment of Acute Myeloid Leukemia (AML). The WiNK trial will enroll 33 AML patients at eight clinical sites based in five European countries. oNKord is the company s first-generation off-the-shelf allogeneic NK cellular immunotherapy product. Glycostem is furthermore developing a range of second (CAR-NK) and third generation (TCR-NK) NK products in-house.
Share:
OSS, Netherlands, Dec. 15, 2020 /PRNewswire/
Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic off-the-shelf Natural Killer (NK) cells, today announced that the first patient has been dosed in its pivotal phase I/IIa trial of oNKord
® for the treatment of Acute Myeloid Leukemia (AML). The WiNK trial will enroll 33 AML patients at eight clinical sites based in five European countries. oNKord
® is the company s first-generation off-the-shelf allogeneic NK cellular immunotherapy product. Glycostem is furthermore developing a range of second (CAR-NK) and third generation (TCR-NK) NK products in-house. We are thrilled about the first patient being dosed in this pivotal trial. This important milestone potentially paves the way for a positive impact on the lives of patients with AML who are at high risk of relapse. The preliminary efficacy data obtained with oNKord